(IN BRIEF) Novartis will present 19 abstracts at the 2025 European Society of Cardiology (ESC) Congress in Madrid, showcasing new findings across its cardiovascular portfolio. Key highlights include two VictORION studies on Leqvio’s impact on quality of life and its … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged abelacimab, atrial fibrillation, AZALEA-TIMI 71, cardiovascular disease, cardiovascular pipeline therapies, Chagas disease, Entresto, ESC Congress 2025, European Society of Cardiology, heart failure, inclisiran, Leqvio, lipoprotein apheresis, lipoprotein(a), Lp(a)FRONTIERS APHERESIS trial, Novartis, PARACHUTE-HF trial, pelacarsen, Sacubitril Valsartan, VictORION studies, xRNA platform
Leicester, UK, 15-12-2014 — /EuropaWire/ — A team from the University of Leicester and Leicester’s Hospitals has played a vital role in identifying a new treatment for reducing the risk of death or emergency hospital admission among patients with serious … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?